News & insights

Aligned incentives and integrated care help address rising specialty costs and improve the patient experience

In the latest episode of the “Pharmacy Friends” podcast, Prime experts explore the personal impact of Alzheimer’s disease, evidence-based ways to support brain health and a growing pipeline

As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.

Patients with pulmonary fibrosis wait about two years for a diagnosis. Rachael Prusi of Prime Therapeutics explains how health plans can find them sooner.

Prime Therapeutics' Pat Gleason, Pharm.D., outlined T1D screening gaps for plans and his priorities as incoming AMCP president